The spectrum of neurologic disease associated with anti-GM1 antibodies

S. A. Sadiq, F. P. Thomas, K. Kilidireas, S. Protopsaltis, A. P. Hays, K. W. Lee, S. N. Romas, N. Kumar, L. Den Van Berg, M. Santoro, D. J. Lange, D. S. Younger, R. E. Lovelace, W. Trojaborg, W. H. Sherman, J. R. Miller, J. Minuk, M. A. Fehr, R. I. Roelofs, D. HollanderFenwick T Nichols, H. Mitsumoto, J. J. Kelley, Thomas Robert Swift, T. L. Munsat, N. Latov

Research output: Contribution to journalArticlepeer-review

197 Scopus citations


We compared anti-GM1 IgM antibody titers in patients with various neurologic diseases and in normal subjects. We found increased titers in patients with lower motor neuron disease, sensorimotor neuropathy, or motor neuropathy with or without multifocal conduction block. In patients with other diseases, titers are similar to those in normal individuals, suggesting that anti-GM1, antibody levels are not increased nonspecifically after neural injury or inflammatory diseases. Anti- GM1, antibodies in many of the patients occur as monoclonal gammopathies, predominantly of lambda light-chain type, but the antibodies are sometimes polyclonal with normal or increased serum IgM concentrations. Most of the anti-GM1, antibodies appear to react with the Gal(pl-3)GalNAc epitope which is shared with asialo-GM1, and GD1,b, but in some patients the antibodies are more specific for GM1, and associated with motor neuropathy. Patients with motor or sensorimotor peripheral neuropathy or lower motor neuron disease should be tested for anti-GM, antibodies or anti-Gal(pi-3)GalNAc antibodies, as therapeutic reduction in antibody concentrations was reported to result in clinical improvement in some patients.

Original languageEnglish (US)
Pages (from-to)1067-1072
Number of pages6
Issue number7
StatePublished - Jul 1990

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'The spectrum of neurologic disease associated with anti-GM1 antibodies'. Together they form a unique fingerprint.

Cite this